S&P 500   4,595.68 (+1.39%)
DOW   35,463.80 (+1.24%)
QQQ   372.60 (+1.67%)
AAPL   169.23 (+1.80%)
MSFT   310.68 (+2.42%)
FB   324.78 (+1.62%)
GOOGL   2,745.67 (+1.60%)
AMZN   3,139.63 (+0.44%)
TSLA   1,034.52 (+3.90%)
NVDA   253.88 (+1.28%)
BABA   132.59 (+3.80%)
NIO   30.40 (+6.18%)
AMD   126.71 (-1.22%)
CGC   7.93 (+3.80%)
MU   89.51 (-0.54%)
GE   101.23 (+0.61%)
T   27.31 (+0.11%)
F   22.62 (+0.76%)
DIS   151.47 (+0.91%)
AMC   18.89 (+3.11%)
PFE   53.58 (+0.07%)
ACB   4.98 (+2.47%)
BA   219.92 (+1.31%)
S&P 500   4,595.68 (+1.39%)
DOW   35,463.80 (+1.24%)
QQQ   372.60 (+1.67%)
AAPL   169.23 (+1.80%)
MSFT   310.68 (+2.42%)
FB   324.78 (+1.62%)
GOOGL   2,745.67 (+1.60%)
AMZN   3,139.63 (+0.44%)
TSLA   1,034.52 (+3.90%)
NVDA   253.88 (+1.28%)
BABA   132.59 (+3.80%)
NIO   30.40 (+6.18%)
AMD   126.71 (-1.22%)
CGC   7.93 (+3.80%)
MU   89.51 (-0.54%)
GE   101.23 (+0.61%)
T   27.31 (+0.11%)
F   22.62 (+0.76%)
DIS   151.47 (+0.91%)
AMC   18.89 (+3.11%)
PFE   53.58 (+0.07%)
ACB   4.98 (+2.47%)
BA   219.92 (+1.31%)
S&P 500   4,595.68 (+1.39%)
DOW   35,463.80 (+1.24%)
QQQ   372.60 (+1.67%)
AAPL   169.23 (+1.80%)
MSFT   310.68 (+2.42%)
FB   324.78 (+1.62%)
GOOGL   2,745.67 (+1.60%)
AMZN   3,139.63 (+0.44%)
TSLA   1,034.52 (+3.90%)
NVDA   253.88 (+1.28%)
BABA   132.59 (+3.80%)
NIO   30.40 (+6.18%)
AMD   126.71 (-1.22%)
CGC   7.93 (+3.80%)
MU   89.51 (-0.54%)
GE   101.23 (+0.61%)
T   27.31 (+0.11%)
F   22.62 (+0.76%)
DIS   151.47 (+0.91%)
AMC   18.89 (+3.11%)
PFE   53.58 (+0.07%)
ACB   4.98 (+2.47%)
BA   219.92 (+1.31%)
S&P 500   4,595.68 (+1.39%)
DOW   35,463.80 (+1.24%)
QQQ   372.60 (+1.67%)
AAPL   169.23 (+1.80%)
MSFT   310.68 (+2.42%)
FB   324.78 (+1.62%)
GOOGL   2,745.67 (+1.60%)
AMZN   3,139.63 (+0.44%)
TSLA   1,034.52 (+3.90%)
NVDA   253.88 (+1.28%)
BABA   132.59 (+3.80%)
NIO   30.40 (+6.18%)
AMD   126.71 (-1.22%)
CGC   7.93 (+3.80%)
MU   89.51 (-0.54%)
GE   101.23 (+0.61%)
T   27.31 (+0.11%)
F   22.62 (+0.76%)
DIS   151.47 (+0.91%)
AMC   18.89 (+3.11%)
PFE   53.58 (+0.07%)
ACB   4.98 (+2.47%)
BA   219.92 (+1.31%)
NASDAQ:SYRS

Syros Pharmaceuticals Stock Forecast, Price & News

$2.37
+0.01 (+0.42%)
(As of 01/20/2022 11:27 AM ET)
Add
Compare
Today's Range
$2.32
$2.44
50-Day Range
$2.36
$4.26
52-Week Range
$2.34
$15.25
Volume
10,078 shs
Average Volume
356,685 shs
Market Capitalization
$146.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.81
30 days | 90 days | 365 days | Advanced Chart
Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Syros Pharmaceuticals logo

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Headlines

Syros outlines clinical updates and 2022 goals
January 11, 2022 |  seekingalpha.com
Syros to Participate in Upcoming Investor Conferences
November 16, 2021 |  finance.yahoo.com
Earnings Preview For Syros Pharmaceuticals
November 4, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
103
Year Founded
N/A

Sales & Book Value

Annual Sales
$15.09 million
Book Value
$1.61 per share

Profitability

Net Income
$-84.04 million
Net Margins
-434.32%
Pretax Margin
-434.32%

Debt

Price-To-Earnings

Miscellaneous

Free Float
54,575,000
Market Cap
$146.81 million
Optionable
Optionable

Company Calendar

Last Earnings
11/05/2021
Today
1/20/2022
Next Earnings (Estimated)
3/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.27 out of 5 stars

Medical Sector

306th out of 1,415 stocks

Pharmaceutical Preparations Industry

136th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

Is Syros Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals
or view top-rated stocks.

How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYRS shares have decreased by 54.0% and is now trading at $2.37.
View which stocks have been most impacted by COVID-19
.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Syros Pharmaceuticals
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its earnings results on Friday, November, 5th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.03. The firm earned $5.70 million during the quarter, compared to the consensus estimate of $5.10 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 77.65% and a negative net margin of 434.32%. During the same period last year, the firm earned ($0.43) EPS.
View Syros Pharmaceuticals' earnings history
.

What price target have analysts set for SYRS?

3 equities research analysts have issued 1-year price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $10.00 to $23.00. On average, they expect Syros Pharmaceuticals' stock price to reach $16.40 in the next twelve months. This suggests a possible upside of 592.0% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Nancy A. Simonian, President, Chief Executive Officer & Director
  • Gerald E. Quirk, Chief Operating Officer
  • Jason Haas, Chief Financial Officer
  • Eric R. Olson, Chief Scientific Officer
  • David A. Roth, Chief Medical Officer

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LGT Capital Partners LTD. (0.81%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Mark J Alles, Richard A Young and Srinivas Akkaraju.
View institutional ownership trends for Syros Pharmaceuticals
.

Which institutional investors are buying Syros Pharmaceuticals stock?

SYRS stock was purchased by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD..
View insider buying and selling activity for Syros Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $2.37.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals has a market capitalization of $146.81 million and generates $15.09 million in revenue each year. The company earns $-84.04 million in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

Syros Pharmaceuticals employs 103 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

Where are Syros Pharmaceuticals' headquarters?

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 744-1340 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.